Systemic therapies for hepatocellular carcinoma.

作者: Daniel H Palmer , Syed A Hussain , Philip J Johnson

DOI: 10.1517/13543784.13.12.1555

关键词:

摘要: For the minority of patients with hepatocellular carcinoma (HCC), surgical or locally ablative therapies may offer prospect cure. However, majority present advanced disease such that treatment curative intent is no longer possible. some these patients, good hepatic reserve and a patent portal venous system, chemoembolisation afford modest survival benefit. The remainder are frequently treated systemic palliative intent. This review aims to summarise current approaches for HCC in adjuvant setting before reviewing evidence novel emerging this field. At there number interesting therapeutic agents potential activity HCC. challenge now design clinical trials optimally evaluate agents.

参考文章(92)
C. Hsu, L.-T. Chen, M.-Y. Lai, K.-H. Yeh, P.-H. Lee, A.-L. Cheng, Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)- and hepatitis C (HCV)-related hepatocellular carcinoma (HCC) Journal of Clinical Oncology. ,vol. 22, pp. 4198- 4198 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.4198
Yasutoshi Muto, Hisataka Moriwaki, Mitsuo Ninomiya, Sadashi Adachi, Akiko Saito, Ken Takeshi Takasaki, Takuji Tanaka, Kaito Tsurumi, Masataka Okuno, Eiichi Tomita, Toshiyuki Nakamura, Takao Kojima, Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 334, pp. 1561- 1567 ,(1996) , 10.1056/NEJM199606133342402
Ruey-Long Hong, Yun-Long Tseng, A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma Cancer Chemotherapy and Pharmacology. ,vol. 51, pp. 433- 438 ,(2003) , 10.1007/S00280-003-0583-2
Ikuo Saiki, Hiroaki Sakurai, Mitsuhiro Matsuo, ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Molecular Cancer Therapeutics. ,vol. 2, pp. 557- 561 ,(2003)
Charles L. M. Olweny, Tom Toya, Edward Katongole-Mbidde, Josua Mugerwa, Sebastian K. Kyalwazi, Herman Cohen, Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication Cancer. ,vol. 36, pp. 1250- 1257 ,(1975) , 10.1002/1097-0142(197510)36:4<1250::AID-CNCR2820360410>3.0.CO;2-X
Winnie Yeo, Kenneth K. Chan, Geoffrey Mukwaya, Michael Ross, W. T. Leung, Stephen Ho, A. T. C. Chan, Philip J. Johnson, Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes Cancer Chemotherapy and Pharmacology. ,vol. 44, pp. 124- 130 ,(1999) , 10.1007/S002800050956
Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui‐Chee Wu, Gerald Chee‐Bunn Chan, Hsiang‐Ju Lin, None, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. ,vol. 62, pp. 479- 483 ,(1988) , 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L
Shuichi Okada, Nobuo Okazaki, Haruhiko Nose, Yasuhiro Shimada, Masaki Yoshimori, Kazunori Aoki, A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. ,vol. 50, pp. 22- 26 ,(1993) , 10.1159/000227142
Josep M. Llovet, Margarita Sala, Lluís Castells, Yanette Suarez, Ramon Vilana, Lluís Bianchi, Carmen Ayuso, Víctor Vargas, Joan Rodés, Jordi Bruix, Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. ,vol. 31, pp. 54- 58 ,(2000) , 10.1002/HEP.510310111